Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial

A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500 kcal d...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of cancer Ročník 95; číslo 6; s. 705 - 709
Hlavní autoři:	Michel, P, Adenis, A, Fiore, F Di, Boucher, E, Galais, M P, Dahan, L, Mirabel, X, Hamidou, H, Raoul, J L, Jacob, J H, Hellot, M F, Prod'Homme, S, Paillot, B
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 18.09.2006 Nature Publishing Group
Témata:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Cancer Research Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - radiotherapy Cisplatin - administration & dosage Cisplatin - adverse effects Clinical Study Combined Modality Therapy - adverse effects Deglutition Disorders - etiology Dose Fractionation, Radiation Drug Resistance Epidemiology Esophageal Neoplasms - drug therapy Esophageal Neoplasms - radiotherapy Female Humans Irinotecan Male Medical sciences Middle Aged Molecular Medicine Neoplasm Staging Oncology Remission Induction Survival Rate Treatment Outcome Tumors induction chemotherapy oesophageal cancer exclusive chemo-radiotherapy Antineoplastic agent Digestive system Enzyme Concurrent DNA topoisomerase Enzyme inhibitor Malignant tumor Radiotherapy oesophageal cancer exclusive chemo-radiotherapy Cisplatin Esophagus Irinotecan Alkylating agent Chemotherapy Isomerases Cancerology Treatment Surgery Phase II trial Platinum II Complexes Cancer
ISSN:	0007-0920, 1532-1827
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500 kcal day −1 were included. Chemotherapy, with cisplatin 30 mg m −2 and irinotecan 60 mg m −2 , was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44–79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4–72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3–77.3%) and 27.9% (95% CI, 13.4–41.3%), respectively. In conclusion, cisplatin–irinotecan–radiotherapy is an active and well-tolerated regimen feasible in out-patients.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23
ISSN:	0007-0920 1532-1827
DOI:	10.1038/sj.bjc.6603328